Premium
Toxic epidermal necrolysis in acquired immunodeficiency syndrome treated with intravenous gammaglobulin
Author(s) -
Phan Tri G,
Wong Richard Cw,
Crotty Kerry,
Adelstein Stephen
Publication year - 1999
Publication title -
australasian journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.67
H-Index - 53
eISSN - 1440-0960
pISSN - 0004-8380
DOI - 10.1046/j.1440-0960.1999.00347.x
Subject(s) - toxic epidermal necrolysis , medicine , rash , culprit , nevirapine , gamma globulin , dermatology , erythroderma , gastroenterology , immunology , antibody , human immunodeficiency virus (hiv) , myocardial infarction , antiretroviral therapy , viral load
A 31‐year‐old man with the acquired immunodeficiency syndrome who developed toxic epidermal necrolysis (TEN) was successfully treated with intravenous immunoglobulin. He presented with a widespread, blistering skin rash, extensive mucosal ulceration, high‐grade fever and pancytopaenia. Nevirapine, a non‐nucleoside reverse transcriptase inhibitor, was suspected as the culprit drug, although the patient had been taking this medication for 6 months. The patient also demonstrated an increased number of gamma/delta (γδ) T cells that decreased concomitantly with his clinical improvement. This correlation has not been described in TEN previously and may be of pathophysiological significance.